Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
Q4 2014 Isis Pharmaceuticals Earnings Conference Call (Replay)
02/27/15 at 10:30 a.m. ET
Q4 2014 Isis Pharmaceuticals Earnings Conference Call
Friday, February 27, 2015 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 1.76 (2.57%)
Data as of 03/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
03/02/15Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., March 2, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  "We are very pleased with the progress we are making with ISIS-TTRRx, and plan to report data from the Phase 2/3 study in 2017.  We have many patients who have completed the fifteen months of dosing and are now recei... 
Printer Friendly Version
02/27/15Isis Reports Financial Results and Highlights for 2014
- Isis Outperforms 2014 Projections for Pro Forma Net Operating Loss and Year-end Cash - Isis Achieves Profitable Fourth Quarter - More than $230 Million in Payments from Partners Drives Significantly Improved Financial Results - Conference Call Webcast Friday, February 27, 10:30 a.m. ET at CARLSBAD, Calif., Feb. 27, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced it significantly outperformed both its pro forma net operating loss (NOL... 
Printer Friendly Version
02/24/15ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
CARLSBAD, Calif., Feb. 24, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-PKKRx.  In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).  HAE is a severe and rare genetic disease that is ... 
Printer Friendly Version
02/20/15Webcast Alert: Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call
CARLSBAD, Calif., Feb. 20, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:        Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call When:    Friday, February 27 at 10:30 a.m. ET / 7:30 a.m. PT Where: How:       Live on the Internet.  Simply log onto our website... 
Printer Friendly Version
Upcoming EventsMore >>
03/04/15 9:20 a.m. ET
Cowen & Company 35th Annual Health Care Conference
27th Annual ROTH Conference
LocationLaguna Niguel, CA
CHI Extracellular Biomarkers Summit
LocationCambridge, MA
83rd European Atherosclerosis Society Congress
LocationGlasgow, UK
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.


Receive Isis alerts in your email.

Sign Up